CoreLab Partners are actively engaged in exciting drug development news and leading industry events. Our experts are key opinion leaders in their respective areas, frequently providing commentary for industry publications and facilitating discussions at key events.
Check this section regularly to read the latest CoreLab news and find out where you can meet with CoreLab Partner staff.
BioClinica Announces Availability of Express EDCplus
– Robust yet Easy-to-Use Program Increases Sponsor Control Over Clinical Trial Timelines –
BioClinica®, Inc., a global provider of clinical trial management services, today announced the immediate availability of BioClinica Express EDCplus. Through the web-based EDCplus program, sponsors and CROs personnel can now directly build their own Express EDC (electronic data capture) studies. The program offers full access to the same system that BioClinica created to build thousands of studies over 15 years, without compromising on power or performance.
BioClinica WebSend is an electronic data transfer solution that offers significant value over other methods to collect and manage medical images for clinical trials. Investigator sites use WebSend to securely transmit medical images for clinical trials over the internet. Pharmaceutical clinical trial sponsors prefer WebSend to outdated alternatives and courier services because it improves the quality of their trial data, makes clinical imaging data immediately available for review, and reduces costs of conducting an imaging-based clinical trial.
BioClinica®, Inc. a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in, and speak at several upcoming industry conferences in April, May, and June. BioClinica experts will discuss industry trends and demonstrate the company's suite of technologies and solutions. The conferences include:
BIOCLINICA AND CORELAB PARTNERS ARE ONE
- Combined Company Creates Clear Leader for Imaging Core Lab Services -
NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced today that JLL Partners and Ampersand Capital Partners, two leading middle market private equity firms, have completed their acquisition of BioClinica and CoreLab Partners and have combined the two companies under the name BioClinica.
JLL PARTNERS TO ACQUIRE BIOCLINICA, INC., AND CORELAB PARTNERS
Transaction to create an industry leading provider of medical imaging and eClinical solutions for clinical trials
BioClinica®, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, today announced that it has entered into a definitive agreement to be acquired by a holding company controlled by JLL Partners, Inc., a leading private equity firm.
Simultaneously, JLL Partners announced that it has reached a definitive agreement to acquire CoreLab Partners, Inc., a provider of medical imaging solutions and cardiac safety services based in Princeton, N.J.
Following the proposed acquisitions, BioClinica and CoreLab Partners will be merged to create a leading provider of medical imaging services and best-in-class eClinical solutions for clinical trials. Ampersand Capital Partners, which is the majority owner of CoreLab Partners, will also be a significant investor in the combined company.
CoreLab Partners enters the early Alzheimer’s imaging market space
Princeton, NJ. December 6, 2012 – CoreLab Partners, Inc, a leading independent core lab providing centralized cardiac safety services and medical imaging assessment, has launched new imaging capabilities targeted at the utilization of independent central image review in the detection of early Alzheimer’s disease.
Princeton, NJ May 15, 2012 – CoreLab Partners, Inc, a leading independent core lab providing centralized cardiac safety services and medical imaging assessment, is set to attend and actively participate in several upcoming industry events around the world over the next several months.
March 2012 -- CoreLab Partners, Inc. recently announced the opening of their new Japan office this January as the first step in their plans to grow their business in Asia. The result of a merger between medical imaging science and cardiac safety supply leaders Medifacts International and RadPharm, Inc. in February 2010, CoreLab Partners provides solutions for the collection, analysis and management of patient images and cardiac safety and efficacy information for clinical trials. With offices in North America, Europe and Asia, CoreLab Partners is a global leader in the medical imaging and cardiovascular corelab market sector.
Princeton, NJ January 17, 2012 – Signaling a further commitment to expand its business model in the Pacific Rim and building a global presence as one of the largest imaging and cardiac safety core labs in the world,CoreLab Partners, Inc., today has announced the opening of an office in Tokyo, Japan under the wholly owned subsidiary of CoreLab Partners Japan, K.K.
Princeton, NJ October 24, 2011 – CoreLab Partners, Inc. has launched a new semi automated ECG solution through its ongoing collaboration with Analyzing Medical Parameters for Solutions (A.M.P.S.) LLC.
“We are pleased to announce the release of our new semi-automated CalECG v3 solution for the analysis of ECGs” said CoreLab Partners’ President and Chief Executive Officer, Dr. Mike Woehler. “This new application represents our commitment to advancing technologies in the cardiac safety market sector and complements our established processes in our proprietary WebHeart® technology platform” added Woehler.
Princeton, NJ June 17, 2011 – CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm, Inc and Medifacts International, will showcase several new technological solutions to coincide with the upcoming DIA meeting in Chicago, Illinois to be held from June 20 - 23, 2011.
Princeton, NJ March 25, 2011 – CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm, Inc and Medifacts International, is set to attend and actively participate in several upcoming industry events around the world over the next two weeks.
Princeton, NJ January 10, 2011 – CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm, Inc and Medifacts International, has launched a new advanced imaging application named ImagEngine.®
Princeton, NJ October 15, 2010 – CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm Inc. and Medifacts International in February of this year, has launched a full suite of imaging service solutions and quality assurance processes as it relates to Dual Energy X-Ray Absorptiometry (DXA).
Princeton, NJ USA October 6, 2010 – CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm and Medifacts International in February of this year, has recently completed the first ever regulatory mandated Thorough QT (TQT) study conducted in the Asia Pacific Rim and the first TQT study for a Japanese new drug application (NDA).
CoreLab Partners, Inc, the recently established global entity resulting from the merger between RadPharm and Medifacts International, has launched a new brand identity to reinforce their capabilities as one of the largest imaging sciences and cardiac safety core labs in the market today.
RadPharm, Inc. a leading Imaging Core Laboratory and Medifacts International, Inc, a leading Cardiovascular Core Laboratory today announced the merger of their business operations. The combined company will be named CoreLab Partners (“CoreLabs”) and will have its corporate headquarters in Princeton, New Jersey.
Core laboratories Rad-Pharm and Medifacts International recently merged business operations, hoping to attract new clients with their combined portfolios.
See a pdf of the original publication here
RadPharm Inc, a global provider of centralized medical image management services to the Biopharmaceutical and medical device industries, was recognized as the third-ranked company among the fifty nominated as one of "New Jersey’s Finest” in 2009.
MEDIFACTS INTERNATIONAL, INC., one of the largest global providers of noninvasive cardiovascular diagnostic services, today announced that they have achieved a company milestone with 10,000 clinical trial sites spread across five continents currently under management.